Ageing-Associated Decline in Intrinsic Capacity: Comprehensive Research Report

1. Disease Information

Overview. Intrinsic capacity (IC) is a construct introduced by the World Health Organization (WHO) as "the composite of all physical and mental capacities that a person can draw on... including their biological reserve" (WHO ICOPE framework). IC is one of the two pillars (alongside the environment) that determine an older person's functional ability in WHO's healthy-ageing model. "Ageing-associated decline in intrinsic capacity" (AADIC) is the clinical entity denoting the age-related, progressive attrition of this composite reserve — a graded, largely subclinical process that precedes and predicts frailty, disability, and death rather than a single-organ disease.

IC is operationalized across five domains: locomotion (balance, gait, muscle strength), vitality (the balance between energy production and consumption — considered an "overarching" domain reflecting underlying biological reserve), cognition (memory, intelligence, problem-solving), psychological (mood, sociability), and sensory function (hearing, vision) (PubMed scoping review, 2022; ScienceDirect vitality review, 2025).

Key identifiers: - ICD-11: MG2A — "Ageing associated decline in intrinsic capacity," under General Symptoms/Signs, which replaced the older, non-clinical "old age" designation (findacode.com; Lancet Healthy Longevity, 2022). - WHO framework: Integrated Care for Older People (ICOPE), published 2017–2019, operationalizing IC screening, assessment and management (PMC9819593). - MONDO/OMIM/Orphanet do not carry dedicated single-gene entries for this construct (it is a geroscience/functional syndrome rather than a Mendelian disease); MONDO indexing, where present, typically cross-references the ICD-11 MG2A code.

Synonyms/alternative names: age-related decline in intrinsic capacity; loss of intrinsic capacity; IC decline; (informally, and imprecisely) "biological ageing decline" — distinct from frailty and disability, discussed in §9 below.

Data provenance. Most evidence is derived from aggregated cohort/population-level resources — large longitudinal ageing cohorts (UK Biobank, Canadian Longitudinal Study on Aging [CLSA], English Longitudinal Study of Ageing [ELSA], China Health and Retirement Longitudinal Study [CHARLS], I-Lan Longitudinal Aging Study, 10/66 Dementia Research Group cohorts, MAPT study) and WHO ICOPE pilot/implementation studies — rather than individual EHR case reports, since IC is fundamentally a population health/geroscience screening construct.

2. Etiology

Disease causal factors. AADIC is not caused by a single lesion but by the cumulative, multisystem action of the fundamental "hallmarks of aging" (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis), which erode reserve capacity across the five IC domains in parallel (Frontiers, hallmarks-of-aging framework, 2024; PMC12259695, "Targeting the hallmarks of aging," 2024).

Genetic risk factors

A 2025 genome-wide association study (GWAS; UK Biobank n=44,631 and CLSA n=13,085; total 57,716) found: - SNP-based heritability of IC: 25.2% (95% CI 23.2–27.2%) in UK Biobank, 19.5% (95% CI 14.2–24.8%) in CLSA. - 38 independent SNPs across 10 novel genomic loci, mapping ~4,289 candidate SNPs to 197 genes. - Lead signal: rs9891103 near MAPT (p = 6.50×10⁻¹⁴). - Other implicated genes: PTP4A2, PRPF3, LCORL, RN7SL89P, ANAPC10, HK1, DLEU1, SCN4A, STAU1. - Implicated pathways: cell cycle/proliferation, apoptosis and cellular senescence, synaptic vesicle trafficking/neuronal plasticity, glucose metabolism/energy production, immune/inflammatory signaling, ubiquitin-proteasome pathway — with tissue enrichment in muscle, brain, heart, adipose, and nerve, matching the five IC domains (PMC12510315; medRxiv preprint). - APOE genotype and polygenic risk score for dementia interact with baseline IC to modify dementia risk in a UK Biobank prospective cohort (Neurology, 2024, PMID 38843484). - IC assessed via 4 domains combined with genetic risk predicts incident Parkinson disease (Neurology, 2024).

Environmental / lifestyle risk factors

Physical inactivity/sedentary behavior: longitudinal data (Seniors-ENRICA-2, Spain) link physical activity and sedentary time to changes in IC trajectory (Lancet Healthy Longevity, 2024).
Diet, smoking, alcohol are recognized modifiable correlates, though evidence quality for movement-behavior specifically remains limited.
Socioeconomic status and sex: low socioeconomic status and female sex are inversely associated with IC in several cohorts.
Living/built environment: better living environment quality is positively associated with IC.
Air pollution (PM1, PM2.5, PM10): associated with elevated stroke and frailty risk in CHARLS and meta-analytic data, plausibly via systemic inflammation/oxidative stress accelerating sarcopenia and vascular injury (PMC12159732; Nature Communications, IC-stroke cohort study).
Social participation is protective against IC decline (CHARLS analysis, MDPI 2026).

Protective factors

Higher baseline physical activity, social engagement, favorable living environment, and (per the multi-domain intervention trials in §12) structured exercise/nutrition/cognitive-training programs slow or partially reverse IC decline, particularly in pre-frail individuals with lower baseline IC (TIGER trial).

Gene-environment interaction

The interaction of polygenic dementia risk with IC trajectory (UK Biobank) is the clearest documented G×E-type interaction: genetically high-risk individuals with declining IC show amplified dementia incidence, suggesting IC decline unmasks or accelerates latent genetic risk rather than acting purely additively (PMID 38843484).

3. Phenotypes

IC decline manifests as a constellation of graded (not binary) functional impairments across the five domains, captured operationally by the WHO ICOPE Screening Tool (six practical sub-domains: locomotion, vitality/nutrition, vision, hearing, cognition, psychological/depressive symptoms) (PMC9945724).

Table (click to expand)

Domain	Representative phenotype	Suggested HPO term	Measurement/cutoff
Locomotion	Reduced gait speed	HP:0002136 (Gait disturbance) / HP:0031936 (Slow walking)	<1.0 m/s on 6-meter timed walk
Locomotion	Impaired sit-to-stand / muscle weakness	HP:0001324 (Muscle weakness)	Unable to complete 5 chair rises in 14 s
Vitality	Unintentional weight loss	HP:0001824 (Weight loss)	Self-reported weight/appetite loss
Vitality	Fatigue	HP:0012378 (Fatigue)	Self-report fatigue scales
Cognition	Memory impairment	HP:0002354 (Memory impairment)	Failure on 3-word recall
Cognition	Disorientation	HP:0031466 (disorientation-related)	Incorrect time/space orientation
Psychological	Depressive symptoms	HP:0000716 (Depressivity)	Geriatric Depression Scale items
Sensory	Hearing loss	HP:0000365 (Hearing impairment)	Whisper test/audiometry
Sensory	Visual impairment	HP:0000505 (Visual impairment)	Self-report/near-vision testing

Onset/severity/progression. Onset is insidious, beginning well before old age in some domains but clinically salient from the 60s–70s; severity is graded and multidimensional (each domain can decline independently); progression is generally gradual but accelerates near end of life — "the magnitude of the inverse association between intrinsic capacity and disability increased as death approached" (Lancet Healthy Longevity, "dynamic relationship"). A 20-year national longitudinal cohort study describes multiple distinct IC decline trajectories rather than one uniform slope (PMC11567246).

Frequency. Pooled meta-analytic prevalence of decreased IC in community-dwelling older adults: 67.8% (15 studies, n=33,070) in a 2024 meta-analysis (PMID 39088112); an earlier 2023 meta-analysis reported a 76.1% detection rate (PMID 37543528) — variability reflects different screening cutoffs/tools across studies.

Quality of life impact. IC decline is associated with reduced functional independence, increased hospitalization/institutionalization risk, and lower quality-of-life scores; the vitality domain in particular correlates with fatigue-driven QoL reduction.

4. Genetic/Molecular Information

Causal/associated genes (GWAS loci): MAPT (lead signal), PTP4A2, PRPF3, LCORL, ANAPC10, HK1, DLEU1, SCN4A, STAU1 (see §2 for details and PMC12510315 citation). These are population-level risk-modifying loci, not single-gene Mendelian causes.
Variant classification: No ACMG/AMP pathogenic-variant framework applies, as IC decline is polygenic/complex rather than Mendelian; GWAS SNPs are common variants of small individual effect (heritability ~20–25% overall).
Modifier genes: APOE genotype modifies the relationship between IC and incident dementia (PMID 38843484).
Epigenetic information: A blood-based DNA methylation "IC clock" has been developed, trained on the five clinical IC domains (cognition, locomotion, psychological well-being, sensory, vitality); this epigenetic IC clock outperforms earlier epigenetic clocks (e.g., PhenoAge/GrimAge-type) in predicting all-cause mortality and correlates with clinical, immunological, and lifestyle factors (Nature Aging, 2025; preprint on bioRxiv).
Chromosomal abnormalities: Not applicable — no described large-scale chromosomal etiology for IC decline as a construct.

Suggested ontology terms: GO:0007568 (aging), GO:0090398 (cellular senescence), GO:0006915 (apoptotic process), GO:0005739 (mitochondrion, GO cellular component), GO:0006914 (autophagy).

5. Environmental Information

Environmental/toxic factors: Ambient air pollution (PM1, PM2.5, PM10) linked to elevated frailty and stroke risk via systemic inflammation/oxidative stress pathways accelerating sarcopenia and vascular injury (PMC12159732).
Lifestyle factors: Physical inactivity/sedentary behavior, poor diet, smoking, alcohol use, and low social participation are recurrently associated with faster IC decline; conversely, physical activity and social engagement are protective (Lancet Healthy Longevity, 2024; MDPI, CHARLS).
Infectious agents: Not a primary etiologic category for IC decline per se, though acute infections (e.g., pneumonia, COVID-19) can precipitate abrupt IC drops via post-acute deconditioning and inflammatory insult — an indirect, exacerbating rather than causal-agent relationship.

6. Mechanism / Pathophysiology

Causal chain (ordered, numbered)

Cell-intrinsic molecular damage accumulates with age — genomic instability, telomere attrition, loss of proteostasis, and epigenetic drift — which leads to dysfunction of the core cellular machinery of energy production and quality control (largely inferred from the broader hallmarks-of-aging literature and extrapolated to IC; direct human causal proof in IC specifically is largely correlational).
Mitochondrial dysfunction develops (impaired biogenesis, excess reactive oxygen species [ROS], defective mitophagy, mtDNA mutation accumulation), which results in reduced ATP production and amplified oxidative stress (PMC12531180; PMC10889427).
Oxidative stress and damage-associated molecular patterns (DAMPs) released via piecemeal mitophagy trigger chronic low-grade sterile inflammation ("inflammaging"), establishing a vicious cycle in which mitochondrial dysfunction amplifies ROS generation, which further accelerates cellular senescence (PMC9246372).
Chronic inflammation and cellular senescence together drive tissue-specific functional decline, branching into the five IC domains:
→ Locomotion branch: inflammaging + mitochondrial dysfunction + hormonal change (e.g., declining anabolic hormones) lead to sarcopenia (loss of muscle mass/strength), manifesting as reduced gait speed and muscle weakness.
→ Vitality branch: impaired mitochondrial oxidative capacity and dysregulated energy/metabolic and neuromuscular/immune-stress-response systems result in reduced physiological reserve, fatigue, and anorexia/weight loss — vitality is proposed as the overarching domain, since energy-metabolism dysfunction plausibly gates the reserve available to the other four domains (ScienceDirect, vitality review, 2025).
→ Cognition branch: neuroinflammation, synaptic loss, and (per the GWAS) MAPT-related tauopathy-adjacent pathways contribute to impaired memory and executive function; this link is corroborated by the APOE/polygenic-risk interaction with IC in predicting dementia.
→ Psychological branch: chronic inflammation and neuroendocrine dysregulation are hypothesized (with weaker direct evidence) to contribute to depressive symptoms and reduced sociability.
→ Sensory branch: age-related structural degeneration of cochlear hair cells and lens/retina (largely independent, tissue-specific ageing processes) leads to hearing and visual impairment, which itself feeds back to worsen cognitive and psychological domains (well-documented sensory-cognitive coupling in the broader ageing literature, though the report found less IC-specific direct evidence for this feedback).
The cumulative, cross-domain erosion of reserve constitutes the ageing-associated decline in intrinsic capacity, which precedes and predicts the downstream clinical states of frailty, disability, and mortality (step is empirically demonstrated: IC decline temporally precedes frailty onset in cohort studies).

Where a step is inferred rather than directly demonstrated for IC as a specific construct (vs. general geroscience), this is noted above (steps 1 and the sensory→cognitive feedback loop) — most of the literature about the general hallmarks-of-aging cascade is generic rather than IC-domain-specific, and the "Biological Rationale for Integrating Intrinsic Capacity Into Frailty Models" review (PMC11890019, not independently readable in this session but summarized in secondary sources) argues IC operationalizes exactly this geroscience cascade clinically.

Domain-specific mechanistic detail

Molecular pathways: cell cycle/apoptosis regulation, ubiquitin-proteasome system, synaptic vesicle trafficking, glucose/energy metabolism, immune/NF-κB inflammatory signaling — all nominated by the IC GWAS gene-set enrichment (PMC12510315).
Cellular processes: cellular senescence (GO:0090398), autophagy/mitophagy (GO:0006914), apoptosis (GO:0006915), chronic low-grade inflammation.
Biomarkers under investigation: interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) as candidate (but not yet sufficiently specific/sensitive) inflammatory correlates of IC decline; plasma ATPase Inhibitory Factor 1 (IF1) studied prospectively in the MAPT cohort as a mitochondrial-function biomarker of IC (medRxiv); IGF-1, DHEA, and hemoglobin proposed as vitality/energy-metabolism biomarkers; GDF15 studied in related mitochondrial-myopathy contexts as a correlate of motor function, though not yet established specifically as an IC vitality biomarker (PMID 38145874; GeroScience 2023).
Epigenetic profiling: the DNA-methylation IC clock (Nature Aging, 2025) is the most advanced multi-omic signature to date, integrating methylation data trained against clinical IC domain scores and validated against mortality.

Suggested GO terms: GO:0007568 (aging), GO:0090398 (cellular senescence), GO:0006954 (inflammatory response), GO:0005739 (mitochondrion), GO:0055114 (oxidation-reduction process). CL terms: CL:0000188 (skeletal muscle myoblast/fiber-related), CL:0000540 (neuron), CL:0000738 (leukocyte, for inflammaging). UBERON: UBERON:0001134 (skeletal muscle tissue), UBERON:0000955 (brain), UBERON:0001846 (columella - inner ear structures, for hearing), UBERON:0000970 (eye).

7. Anatomical Structures Affected

Organ level (primary): skeletal muscle (locomotion), brain/CNS (cognition, psychological), inner ear/cochlea (hearing), eye/retina/lens (vision), and systemic metabolic/endocrine organs (vitality — adipose tissue, liver, pancreas contributing to energy balance).
Secondary/systemic involvement: cardiovascular system (via inflammaging and shared risk factors — IC also predicts stroke risk), immune system (chronic low-grade activation).
Body systems involved: musculoskeletal, nervous, sensory, endocrine/metabolic, immune.
Tissue/cell level: skeletal myofibers (sarcopenia), neurons and glia (cognition), cochlear hair cells, retinal/lens cells, adipocytes and hepatocytes (metabolic reserve), circulating immune cells (inflammaging).
Subcellular level: mitochondria (bioenergetic dysfunction — GO:0005739), lysosomes/autophagosomes (impaired proteostasis/mitophagy), nucleus (epigenetic drift, genomic instability).
Localization/laterality: Generally bilateral/systemic and diffuse rather than focal or lateralized, consistent with a whole-organism, multisystem process rather than a localized lesion.

8. Temporal Development

Onset: insidious ("subacute-to-chronic" in character), beginning in mid-to-late adulthood with detectable domain-specific declines and becoming clinically salient in the 60s onward; some sub-processes (e.g., muscle mass loss) start as early as the 4th–5th decade.
Progression: Not uniform — a 20-year national longitudinal cohort study identified multiple distinct multi-trajectory patterns of IC decline (rather than one single trajectory), each with different downstream age-related outcomes (PMC11567246). The 10/66 cohort natural-history analysis similarly documents domain-specific longitudinal patterns rather than synchronized decline (PMC10387229).
Course pattern: generally progressive, though individual domains may show plateau or partial reversibility (particularly with intervention — see §12); decline accelerates as death approaches ("dynamic relationship" with disability, Lancet Healthy Longevity).
Duration: chronic and, at the population level, essentially universal with advancing age (lifelong once established, absent intervention).
Remission: partial, intervention-induced improvement is documented (see §12) — spontaneous remission is not typical of the underlying biological process, though composite IC scores can improve with rehabilitation of a specific domain (e.g., cataract surgery restoring the sensory domain).
Critical periods: Pre-frail state is repeatedly identified in the literature as the key window of opportunity — the TIGER trial found intervention benefit was most pronounced among those with greater baseline IC impairment, suggesting early-to-moderate decline (rather than end-stage decline) is the critical intervention window (ScienceDirect, TIGER).

9. Inheritance and Population

Epidemiology: - Pooled prevalence of decreased IC among community-dwelling older adults: 67.8% (2024 meta-analysis, 15 studies, n=33,070; PMID 39088112); earlier estimate 76.1% detection rate (PMID 37543528). Estimates vary substantially by screening tool, cutoff, and setting (community vs. inpatient).

Genetic architecture (not classical Mendelian inheritance — complex/polygenic trait): - SNP-heritability ~19.5–25.2% (§2/§4). - No described penetrance/expressivity framework applies (not a single-gene disorder); genetic anticipation, germline mosaicism, and founder effects are not applicable constructs here. - Consanguinity role: not established/applicable. - Carrier frequency: not applicable (polygenic risk, not carrier state).

Population demographics: - Affected populations: all ageing populations globally; the WHO ICOPE framework has been piloted and adopted in diverse settings including China, Singapore, and Latin America/India/China (10/66 cohorts). - Sex: some studies report higher IC decline burden associated with female sex, though this varies by domain and cohort. - Age distribution: prevalence and severity increase monotonically with chronological age; the construct is specifically defined for older adults (typically ≥60 years in WHO framework), though sub-clinical decline is measurable earlier.

Relationship to frailty and disability (conceptual distinction). IC, frailty, and disability are related but distinct constructs:

"Frailty and IC are complementary, with frailty highlighting the need for specialised care in complex cases, whereas IC supports early intervention and prevention across broader populations" (PMC6591451, "Frailty and Intrinsic Capacity: Two Distinct but Related Constructs," PMID 31275941).

IC operates at the level of an individual's underlying physical/mental reserve; frailty is the clinical syndrome of accentuated vulnerability arising when that reserve is depleted; disability is the downstream functional/environmental-interaction outcome. Declines in IC frequently precede frailty and disability onset, supporting IC's role as an earlier, more modifiable target for prevention (PMC9819593; PMC10737867).

10. Diagnostics

WHO ICOPE Screening Tool (the primary standardized instrument) assesses six practical sub-domains:

Table (click to expand)

Sub-domain	Screening method
Locomotion	5 chair-rises in ≤14 seconds test; 6-meter timed walk (<1.0 m/s indicates impairment)
Cognition	Time/space orientation questions + 3-word recall
Vitality/nutrition	Self-reported weight loss and appetite loss
Vision	Self-reported visual difficulty / near-vision testing
Hearing	Whisper test / self-report
Psychological	Depressive symptom screening (e.g., mood questions)

The tool's sensitivity/specificity performance has been evaluated in multiple validation studies, including the VIMCI study (PMC9945724) and a scoping review of sensitivity/specificity across settings (ScienceDirect).

Laboratory/biomarker tests (research/emerging): - Inflammatory panel: IL-6, CRP, TNF-α (candidate, not yet clinically validated for IC-specific staging). - Mitochondrial-function biomarker: plasma IF1 (research use, MAPT cohort). - Vitality/energy-metabolism biomarkers: IGF-1, DHEA, hemoglobin. - Epigenetic/omics: blood-based DNA-methylation "IC clock" — a research-stage but promising quantitative composite biomarker correlating with mortality risk (Nature Aging, 2025).

Genetic testing: Not part of routine clinical diagnosis; GWAS-derived polygenic risk scores (for IC itself, or for correlated outcomes like dementia via APOE/PRS) remain research tools.

Differential diagnosis / distinguishing considerations: Distinguish IC decline from (a) frailty (a downstream clinical syndrome), (b) disability (functional/environmental outcome), and (c) single-organ disease processes that can mimic domain-specific IC decline (e.g., major depressive disorder mimicking the psychological domain, primary sarcopenia versus disuse atrophy, age-related macular degeneration versus other visual pathology) — the ICOPE approach is explicitly a screening/triage tool, not a diagnostic replacement for organ-specific workup.

Screening context: The WHO ICOPE program is structured in five phases: (1) screening for IC decline, (2) in-depth assessment, (3) person-centered care planning, (4) referral, and (5) monitoring; it issues 13 recommendations covering mobility loss, malnutrition, visual/hearing impairment, cognitive impairment, and depressive symptoms, plus modules on urinary incontinence, falls risk, and caregiver support (PMC9819593; WHO ICOPE Module 7).

11. Outcome/Prognosis

IC is a robust, graded predictor of adverse outcomes:

Mortality: In a cohort study, IC was inversely associated with mortality (HR 0.57 per unit increase reported in one analysis); worst-quartile IC associated with 1.48-fold higher mortality risk (attenuated to 1.41 after adjusting for comorbidity); each 1-point increase in IC score associated with a 5% decrease in mortality risk; low IC associated with HR 1.94 for mortality in another analysis; deteriorated IC trajectory associated with mortality HR as high as 4.60 in a further longitudinal study (ScienceDirect, 10-year mortality; PMID 35963450; I-Lan longitudinal aging study, PMC9970311).
Cardiovascular subgroup: Among older patients with cardiovascular disease, higher IC score associated with lower 5-year all-cause mortality (HR 0.79) (PMC12415750).
Functional decline meta-analysis: A 2024 systematic review/meta-analysis of longitudinal studies confirmed IC's association with both functional decline and mortality across pooled cohorts (PMID 38945130; Lancet Healthy Longevity).
Dementia/neurodegeneration: IC decline (especially combined with high polygenic dementia risk or APOE ε4 status) predicts incident dementia and Parkinson disease (PMID 38843484; Neurology 2024, PD; Sydney Memory and Ageing Study, PMC12560156).
Stroke risk: IC is independently associated with incident stroke across multiple cohorts (Nature Communications).
Longevity (extreme age): IC in the 70–100 age range independently associated with longevity outcomes (PMC12759399).
Complications: Higher risk of falls, geriatric syndromes (urinary incontinence), hospitalization, institutionalization, and progression to frailty/disability.
Prognostic biomarkers: The DNA-methylation IC clock outperforms prior epigenetic clocks for mortality prediction, suggesting future clinical utility as a prognostic biomarker.

12. Treatment

IC decline is managed through multidomain, person-centered prevention/rehabilitation rather than pharmacotherapy targeted at a single disease mechanism, consistent with its status as a functional-reserve construct rather than a discrete disease.

Multidomain lifestyle/behavioral interventions (NCIT:C181743 Behavioral Counseling / NCIT:C15302 Physical Therapy / NCIT:C15447 Dietary Intervention): - Combined exercise + cognitive stimulation therapy significantly improved IC composite score and locomotion, vitality, cognition, and psychological sub-scores in pre-frail older adults (PMC12275792, 2024). - TIGER trial (Taiwan, n=1,054): 12-month multidomain intervention (exercise, nutrition, cognitive/social engagement) significantly mitigated cognitive decline and physical frailty, with the largest benefit in those with the greatest baseline IC impairment (ScienceDirect). - ENHANCE RCT: 12-month group-based multidomain intervention (exercise, cognitive training, nutrition education) targeting brain structure/function (PMC12134766). - MIDA study (n=248, ages 60–85): multidomain cognitive training + exercise + nutritional guidance, 12-month follow-up (Tandfonline, 2025). - Multidomain lifestyle counseling RCT in older women showed improved IC (Aging Clinical and Experimental Research, 2025). - Smart-care platform–delivered multi-domain interventions are being tested in ongoing RCT protocols (BMC Geriatrics protocol). - A non-randomized controlled study found baseline IC itself (rather than intervention exposure) was the stronger predictor of reversal to robustness among prefrail adults, underscoring IC's role as both a target and a prognostic moderator of intervention response (PMID 36341237).

Domain-specific treatment (NCIT terms): - Locomotion/sarcopenia: resistance/endurance exercise (NCIT:C15302 Physical Therapy), nutritional protein supplementation, and — in emerging research — pharmacological agents targeting mitochondrial health, senolytics, and exerkines (PMC12531180). - Sensory: cataract surgery, hearing aid provision (device-based; per this repo's convention, bind the surgical/clinical action term, e.g., NCIT:C15329 Surgical Procedure, and capture the device via a qualifier). - Cognitive/psychological: cognitive stimulation therapy, behavioral counseling, social-engagement programs. - Vitality: dietary/nutritional intervention (NCIT:C15447), management of underlying inflammatory/metabolic drivers.

Experimental/advanced therapeutics: Senolytics, exerkines, and gene-therapy approaches targeting mitochondrial dysfunction are cited as emerging, largely pre-clinical/early-clinical strategies for the sarcopenia component of IC decline; no disease-modifying pharmacotherapy is yet approved specifically for "IC decline" as an indication.

Treatment outcomes: Multidomain interventions show consistent, modest-to-moderate improvement in IC composite and domain scores, with the strongest benefit in pre-frail (moderately impaired) individuals — reinforcing the "critical period" concept in §8. A 2024 Lancet Healthy Longevity commentary argues the field has established that "intrinsic capacity assessment works" and the priority now is translating assessment into scaled clinical/public-health action (Lancet Healthy Longevity commentary, 2024).

13. Prevention

Primary prevention: population-level promotion of physical activity, healthy diet, social participation, and reduction of environmental exposures (air pollution) to preserve IC reserve before decline is clinically detectable.
Secondary prevention (screening/early detection): WHO ICOPE screening tool deployment in primary care and community settings as a systematic early-detection strategy — this is the centerpiece of the WHO's global healthy-ageing strategy.
Tertiary prevention: the multidomain intervention programs in §12, aimed at preventing progression from IC decline to frailty and disability once impairment is identified.
Risk stratification: combining IC screening with genetic/polygenic risk information (e.g., dementia PRS + APOE) is an emerging risk-stratification approach to target intensive prevention to the highest-risk subgroups.
Behavioral interventions: exercise and social-participation programs are the most consistently evidence-supported behavioral prevention strategy.
Public health: WHO's ICOPE framework itself functions as a public-health/health-systems intervention, having been piloted and adapted in multiple countries (China, Singapore, Latin America, India) as national/regional healthy-ageing policy (PMC9819593, narrative review of global ICOPE adoption).
Environmental interventions: reducing air pollution exposure is supported as a modifiable public-health lever given documented associations with frailty/stroke risk.

14. Other Species / Natural Disease

IC is increasingly being operationalized as a translational geroscience construct in non-human species:

A 2026 narrative review specifically examines IC evolution during aging in mouse and fish models, summarizing measurement approaches for each of the five IC domains and describing longitudinal IC trajectories in these organisms — explicitly framed as supporting "bidirectional translation" between preclinical geroscience models and human IC (ScienceDirect, 2026).
Taxonomy: Mus musculus (NCBITaxon:10090), zebrafish/other fish models (NCBITaxon varies by species) are the principal model organisms used.
Orthologous genes: Mouse orthologs of the human GWAS-implicated genes (Mapt, Hk1, Scn4a, etc.) are used in preclinical mechanistic work on sarcopenia, neurodegeneration, and metabolic decline, though a dedicated ortholog-mapping study specific to IC as a composite trait was not identified in this search.
Comparative biology: the hallmarks-of-aging framework underlying IC decline (mitochondrial dysfunction, cellular senescence, inflammaging) is evolutionarily conserved, supporting cross-species mechanistic inference, though the search did not surface IC-specific naturally-occurring veterinary disease reports (e.g., OMIA entries) — IC as formally defined is a human/WHO clinical construct, and its animal-model literature is explicitly a translational adaptation rather a naturally arising veterinary diagnosis.

15. Model Organisms

Mouse Frailty Index (FI): The most mature translational tool. Based on cumulative deficit accumulation (originally ~31 invasive/non-invasive measures), the mouse FI shows a characteristic distribution, similar values at comparable life stages, a dose-response relationship with mortality, and a submaximal limit — closely paralleling human deficit-accumulation frailty indices (Scientific Reports, PMID via Nature "srep43068"; PMC4271019, "Clinically Relevant Frailty Index for Mice"). A streamlined, non-invasive FI protocol allows rapid, longitudinal assessment of large mouse cohorts without specialized equipment, enhancing translational throughput for geroscience intervention studies (PMID 28463656).
Fish models: used alongside mice in the 2026 comparative IC-trajectory review, offering a shorter-lived, high-throughput complementary system for longitudinal multi-domain functional aging assessment.
Model characteristics: Mouse FI and emerging IC-domain measures reasonably recapitulate human functional decline trajectories and mortality dose-response relationships, but limitations include incomplete capture of subjective/psychological domains (mood, sociability are harder to operationalize in rodents) and species differences in lifespan/pace-of-ageing that complicate direct translation of intervention timing.
Applications: these models are used to test candidate geroscience interventions (senolytics, exercise mimetics, mitochondrial-targeted compounds, caloric restriction) for their effect on multidomain functional reserve before human trials, and to dissect causal mechanistic steps (e.g., mitochondrial dysfunction → sarcopenia) that are only correlational in human cohort data.
Resources: Mouse Genome Informatics (MGI) and International Mouse Phenotyping Consortium (IMPC) resources support genetic (knockout/conditional) models of individual hallmark-of-aging genes (e.g., mitochondrial quality-control genes) relevant to IC-domain-specific mechanisms, though no centralized "IC model organism" database currently exists analogous to disease-specific OMIA/IMPC catalogs.

Summary of Key Ontology Term Suggestions

Table (click to expand)

Category	Suggested terms
ICD-11	MG2A (Ageing associated decline in intrinsic capacity)
HPO	HP:0002136 (Gait disturbance), HP:0001324 (Muscle weakness), HP:0001824 (Weight loss), HP:0012378 (Fatigue), HP:0002354 (Memory impairment), HP:0000716 (Depressivity), HP:0000365 (Hearing impairment), HP:0000505 (Visual impairment)
GO (Biological Process)	GO:0007568 (aging), GO:0090398 (cellular senescence), GO:0006954 (inflammatory response), GO:0006914 (autophagy), GO:0055114 (oxidation-reduction process)
GO (Cellular Component)	GO:0005739 (mitochondrion)
CL	CL:0000188 (skeletal myofiber-related), CL:0000540 (neuron), CL:0000738 (leukocyte)
UBERON	UBERON:0001134 (skeletal muscle tissue), UBERON:0000955 (brain), UBERON:0000970 (eye)
HGNC	MAPT (HGNC:6893), PTP4A2, PRPF3, LCORL, ANAPC10, HK1, DLEU1, SCN4A, STAU1
NCIT (treatment)	NCIT:C15302 (Physical Therapy), NCIT:C15447 (Dietary Intervention), NCIT:C181743 (Behavioral Counseling), NCIT:C15329 (Surgical Procedure), NCIT:C15986 (Pharmacotherapy)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	42
Resolved	42
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	3
Quoted claims found in source	0
Quoted claims not found in source	3
References weighed for topical relevance	42
On topic	19
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

1 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMC:PMC9819593 (abstract only): "the composite of all physical and mental capacities that a person can draw on... including their biological reserve"
Text part not found as substring: 'the composite of all physical and mental capacities that a person can draw on' (note: only abstract available for PMID:36612480, full text may contain this excerpt)
PMID:31275941: "Frailty and IC are complementary, with frailty highlighting the need for specialised care in complex cases, whereas IC supports early intervention and prevention across broader populations"
closest text in source: "Both frailty and IC are focused at promoting the development of person-centered care plans (ability in detecting one's impairments, needs and preferences) and lead to tailored care/healthy strategies to reverse, slow or arrest the losses"
PMC:PMC6591451: "Frailty and IC are complementary, with frailty highlighting the need for specialised care in complex cases, whereas IC supports early intervention and prevention across broader populations"
closest text in source: "Both frailty and IC are focused at promoting the development of person-centered care plans (ability in detecting one's impairments, needs and preferences) and lead to tailored care/healthy strategies to reverse, slow or arrest the losses"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Table (click to expand)

Outcome	Count
Terms checked	31
Resolved	28
Unresolved (possible confabulation)	0
Obsolete	2
Unverifiable	1
Terms whose name was checked	24
Terms named correctly	13
Terms named as a different term	2
Terms whose name is worth a second look	9

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

HP:0031466 (1 mention) - the report calls it "disorientation-related"; HP calls it Impairment in personality functioning
UBERON:0001846 (1 mention) - the report calls it "columella - inner ear structures, for hearing"; UBERON calls it internal ear

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0007568 (obsolete aging) (3 mentions)
GO:0055114 (obsolete oxidation-reduction process) (2 mentions)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

HP:0000716 (2 mentions) - the report calls it "Depressivity"; HP calls it Depression, and lists "Depressivity" among its other names
GO:0007568 (3 mentions) - the report calls it "aging"; GO calls it obsolete aging, and lists "ageing" among its other names
GO:0090398 (4 mentions) - the report calls it "cellular senescence", "Cellular processes: cellular senescence"; GO calls it cellular senescence**
GO:0005739 (4 mentions) - the report calls it "mitochondrion, GO cellular component", "mitochondrion"; GO calls it mitochondrion
GO:0055114 (2 mentions) - the report calls it "oxidation-reduction process"; GO calls it obsolete oxidation-reduction process
CL:0000188 (2 mentions) - the report calls it "skeletal muscle myoblast/fiber-related"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names
CL:0000738 (2 mentions) - the report calls it "leukocyte, for inflammaging"; CL calls it leukocyte
NCIT:C15447 (3 mentions) - the report calls it "Vitality: dietary/nutritional intervention"; NCIT calls it Dietary Intervention, and lists "Nutritional Interventions" among its other names
NCBITaxon:10090 (1 mention) - the report calls it "Mus musculus", "Taxonomy: *Mus musculus"; NCBITaxon calls it Mus musculus**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

GO:0090398 - called "cellular senescence", "Cellular processes:** cellular senescence"
GO:0005739 - called "mitochondrion, GO cellular component", "mitochondrion"
NCBITaxon:10090 - called "Mus musculus", "Taxonomy:* Mus musculus"